Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders

Journal of Studies on Alcohol and Drugs

Volumn 75, Issue 3, 2014, Pages 467-475

  Knudsen, Hannah K ^a   Roman, Paul M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; DRUGS USED IN THE TREATMENT OF ADDICTION; TAURINE;

ALCOHOL-RELATED DISORDERS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; GOVERNMENT; HEALTH CARE PLANNING; HUMAN; INFORMATION DISSEMINATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRENDS; UNITED STATES; UTILIZATION;

ALCOHOL DETERRENTS; ALCOHOL-RELATED DISORDERS; CROSS-SECTIONAL STUDIES; HEALTH PLAN IMPLEMENTATION; HUMANS; INFORMATION DISSEMINATION; TAURINE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION;

EID: 84901683509     PISSN: 19371888     EISSN: 19384114     Source Type: Journal    
DOI: 10.15288/jsad.2014.75.467     Document Type: Article

References (43)

1. Abraham, A. J., Knudsen, H. K., Rothrauff, T. C., & Roman, P. M. (2010). The adoption and implementation of alcohol pharmacotherapies in the Clinical Trials Network: The infl uence of research network participation. Journal of Substance Abuse Treatment, 38, 275-283.
2. Allison, P. D. (2002). Missing data. Thousand Oaks, CA: Sage. Allison, P. D. (2009). Missing data. In R. E. Millsap & A. Maydeu-Olivares (Eds.), The SAGE handbook of quantitative methods in psychology (pp. 72-89). Thousand Oaks, CA: Sage.
3. Anton, R. F., O'Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Zweben, A., for the COMBINE Study Research Group. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence-The COMBINE study: A randomized controlled trial. Journal of the American Medical Association, 295, 2003-2017.
4. Boothby, L. A., & Doering, P. L. (2005). Acamprosate for the treatment of alcohol dependence. Clinical Therapeutics, 27, 695-714.
5. Carmen, B., Angeles, M., Ana, M., & Maria, A. J. (2004). Effi cacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction, 99, 811-828.
6. Carroll, K. M., Kosten, T. R., & Rounsaville, B. J. (2004). Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug and Alcohol Dependence, 75, 123-134.
7. Center for Substance Abuse Treatment. (2009). Incorporating alcohol pharmacotherapies into medical practice (Treatment Improvement Protocol #49). Rockville, MD: Substance Abuse and Mental Health Services Administration.
8. Ching, A. T., & Ishihara, M. (2012). Measuring the informative and persuasive roles of detailing on prescribing decisions. Management Science, 58, 1374-1387.
9. Colditz, G. A. (2012). The promise and challenge of dissemination and implementation research. In R. C. Brownson, G. A. Colditz, & E. K. Proctor (Eds.), Dissemination and implementation research in health (pp. 3-22). New York, NY: Oxford University Press.
10. Donovan, D. M., Anton, R. F., Miller, W. R., Longabaugh, R., Hosking, J. D., & Youngblood, M. (2008). Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): Examination of posttreatment drinking outcomes. Journal of Studies on Alcohol and Drugs, 69, 5-13.
11. Ducharme, L. J., Knudsen, H. K., & Roman, P. M. (2006). Trends in the adoption of medications for alcohol dependence. Journal of Clinical Pharmacology, 26, S13-S19.
12. Fischer, M. A., Keough, M. E., Baril, J. L., Saccoccio, L., Mazor, K. M., Ladd, E., Gurwitz, J. H. (2009). Prescribers and pharmaceutical representatives: Why are we still meeting? Journal of General Internal Medicine, 24, 795-801.
13. Fishman, M. J., Shulman, G. D., Mee-Lee, D., Kolodner, G., & Wilford, B. B. (Eds.). (2010). ASAM patient placement criteria: Supplement on pharmacotherapies for alcohol use disorders. Philadelphia, PA: Lippincott Williams & Wilkins.
14. Huddle, T. S. (2008). Drug reps and the academic medical center-a case for management rather than prohibition. Perspectives in Biology and Medicine, 51, 251-260.
15. Katz, D., Caplan, A. L., & Merz, J. F. (2010). All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry giftgiving. American Journal of Bioethics, 10, 11-17.
16. Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Wiedemann, K. (2003). Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Archives of General Psychiatry, 60, 92-99.
17. Knudsen, H. K., Abraham, A. J., & Roman, P. M. (2011). Adoption and implementation of medications in addiction treatment programs. Journal of Addiction Medicine, 5, 21-27.
18. Knudsen, H. K., Roman, P. M., & Oser, C. B. (2010). Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Journal of Addiction Medicine, 4, 99-107.
19. Kumana, C. R., Cheung, B. M., & Lauder, I. J. (1999). Gauging the impact of statins using number needed to treat. Journal of the American Medical Association, 282, 1899-1901.
20. Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013). Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful? Addiction, 108, 275-293.
21. Manuel, J. K., Hagedorn, H. J., & Finney, J. W. (2011). Implementing evidence- based psychosocial treatment in specialty substance use disorder care. Psychology of Addictive Behaviors, 25, 225-237.
22. Mark, T. L., Kranzler, H. R., Song, X., Bransberger, P., Poole, V. H., & Crosse, S. (2003). Physicians' opinions about medications to treat alcoholism. Addiction, 98, 617-626.
23. McLellan, A. T., & McKay, J. R. (2009). Integrating evidence-based components into a functional continuum of care. In R. K. Ries, D. A. Fiellin, S. C. Miller, & R. Saitz (Eds.), Principles of addiction medicine (4th ed., pp. 361-378). Baltimore, MD: Lippincott, Williams, and Wilkins.
24. Mee-Lee, D., Gartner, L., Miller, M. M., Shulman, G. R., & Wilford, B. B. (1996). Patient placement criteria for the treatment of substance-related disorders (2nd ed.). Chevy Chase, MD: American Society of Addiction Medicine.
25. Mizik, N., & Jacobson, R. (2004). Are physicians "easy marks"? Quantifying the effects of detailing and sampling on new prescriptions. Management Science, 50, 1704-1715.
26. Morley, K. C., Teesson, M., Reid, S. C., Sannibale, C., Thomson, C., Phung, N., Haber, P. S. (2006). Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction, 101, 1451-1462.
27. Narayanan, S., Desiraju, R., & Chintagunta, P. K. (2004). Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. Journal of Marketing, 68, 90-105.
28. National Institute on Drug Abuse. (2009). Principles of drug addiction treatment: A research-based guide (NIH Publication No. 09-4180). Rockville, MD: Author.
29. Omorphos, S., Hanif, M., & Dunning, J. (2004). Are prophylactic betablockers of benefi t in reducing the incidence of AF following coronary bypass surgery? Interactive Cardiovascular and Thoracic Surgery, 3, 641-646.
30. Richardson, K., Baillie, A., Reid, S., Morley, K., Teesson, M., Sannibale, C., Haber, P. (2008). Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction, 103, 953-959.
31. Rogers, E. M. (2003). Diffusion of innovations (5th ed.). New York, NY: Free Press.
32. Roman, P. M., Abraham, A. J., & Knudsen, H. K. (2011). Using medicationassisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behaviors, 36, 584-589.
33. Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2011). Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews, Issue 9, Article No. CD004332.
34. Rösner, S., Hackl-Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M., & Soyka, M. (2010). Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews, Issue 12, Article No. CD001867.
35. Royston, P. (2004). Multiple imputation of missing values. The Stata Journal, 4, 227-241.
36. Royston, P. (2005a). Multiple imputation of missing values: Update. The Stata Journal, 5, 188-201.
37. Royston, P. (2005b). Multiple imputation of missing values: Update office. The Stata Journal, 5, 527-536.
38. Samet, J. H., Friedmann, P., & Saitz, R. (2001). Benefi ts of linking primary medical care and substance abuse services: Patient, provider, and societal perspectives. Archives of Internal Medicine, 161, 85-91.
39. Sorensen, J. L., Hettema, J. E., & Larios, S. (2009). What is evidence-based treatment? In P. M. Miller (Ed.), Evidence-based addiction treatment (pp. 3-20). Burlington, MA: Academic Press.
40. StataCorp. (2011). Stata multiple-imputation reference manual: Release 12. College Station, TX: Stata Press.
41. Suissa, S. (2013). Number needed to treat in COPD: Exacerbations versus pneumonias. Thorax, 68, 540-543.
42. Velasco, E., Espelage, W., Faber, M., Noll, I., Ziegelmann, A., Krause, G., Eckmanns, T. (2011). A national cross-sectional study on sociobehavioural factors that infl uence physicians' decisions to begin antimicrobial therapy. Infection, 39, 289-297.
43. Whitworth, A. B., Fischer, F., Lesch, O. M., Nimmerrichter, A., Oberbauer, H., Platz, T., Fleischhacker, W. W. (1996). Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. The Lancet, 347, 1438-1442.